HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Rohayem, J. Articles by Frank, K.-H. Search for Related Content PubMed PubMed Citation Articles by Rohayem, J. Articles by Frank, K.-H. Related Collections Molecular Diagnostics and Genetics

Comparison of the Diagnostic Accuracy of Three Commercially Available Enzyme Immunoassays for Anti-p53 Antibodies

¹ Institute for Immunology and
² Department of Surgery, Medical Faculty "Carl Gustav Carus", Technical University Dresden, Dresden 01101, Germany;
^a author for correspondence: fax 49-351-8832778, e-mail rohayem@rcs.urz.tu-dresden.de

The p53 tumor suppressor gene encodes a 53-kDa nuclear phosphoprotein that is thought to protect cells against the accumulation of genetic alterations (1). The p53 phosphoprotein is involved in cycle arrest, apoptosis, inhibition of tumor growth, and preservation of genetic stability (2). Abnormalities of the p53 gene are reported to be the most common genetic alterations in human cancer (3)(4). Mutated p53 gene encodes for mutant p53 proteins that may serve as targets of the host immune system as tumor-specific antigens (5). However, accumulation of the p53 protein in the cell is considered the main cause of anti-p53 antibody production (6). The presence of anti-p53 antibodies has been demonstrated in sera of patients with various cancers (7)(8)(9), including lung (10), breast (11)(12), liver (13), colorectal (14), and prostate cancer, and blood cell malignancies (15).

Anti-p53 antibodies initially were detected by immunoblot and immunoprecipitation with extracts of transformed cells as a source of antigen. In recent years, various ELISAs have been described that use mutant (8) or wild-type (16) p53 as antigen, solid-phase or sandwich methods, and prokaryotically or eukaryotically expressed p53 proteins.

Our purpose was to evaluate the potential of the tests to provide correct diagnostic classification (17). We studied three commercial ELISAs for anti-p53 antibodies by use of ROC curve analysis. We selected 72 patients presenting with suspicion of malignancy (unexplained body weight loss and chronic fatigue associated with chronic rectal hemorrhage and/or intermittent obstipation, hemoptysis, and/or pathognomonic aspect of tumoral development on chest radiographs). Ethics approval by the Ethics Commission of the University of Dresden (Germany) according to the Helsinki Declaration of . . . [Full Text of this Article]

References

The following articles in journals at HighWire Press have cited this article:

				J. Rohayem, P. Diestelkoetter, B. Weigle, A. Oehmichen, M. Schmitz, J. Mehlhorn, K. Conrad, and E. P. Rieber Antibody Response to the Tumor-associated Inhibitor of Apoptosis Protein Survivin in Cancer Patients Cancer Res., April 1, 2000; 60(7): 1815 - 1817. [Abstract] [Full Text]